Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005115 | 0.88 | ACE (0.41) | MTNR1AMEN1KMT2AACE | |
| SCHEMBL3441638 | 0.83 | MTNR1A (0.43) | MTNR1AMEN1KMT2AACE | |
| SCHEMBL3441637 | 0.83 | MTNR1A (0.43) | MTNR1AMEN1KMT2AACE | |
| SCHEMBL7004166 | 0.83 | HSD11B1 (0.35) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7001472 | 0.82 | PARP1 (0.38) | — | |
| SCHEMBL1981597 | 0.82 | MTNR1A (0.44) | MTNR1AACESCN9A | |
| Hydrochloric Acid SCHEMBL15663494 | 0.81 | MTNR1A (0.44) | MTNR1AACESMN1; SMN2SCN9A | |
| SCHEMBL958204 | 0.80 | CHRM2 (0.35) | MEN1KMT2A | |
| SCHEMBL211419 | 0.80 | CHRM2 (0.35) | MEN1KMT2A | |
| SCHEMBL625416 | 0.80 | CHRM2 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | MTNR1A 245/4885MEN1 3836/4885KMT2A 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.